Title

Preserving Public Trust and Demanding Accountability (Introduction to Part II)

Document Type

Book Chapter

Publication Date

2015

Editor(s)

Holly Fernandez Lynch & I. Glenn Cohen

ISBN

9780231540070

Publisher

Columbia University Press

Language

en-US

Abstract

The President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) recently said that “there is one great problem that seriously challenges the ability of America’s research-based pharmaceutical companies to . . . research and develop new cures and treatments. In a word, it is trust” (Pricewaterhouse Coopers’ Health Research Institute 2006). This section includes four chapters that explore the role of the drug and device industries, in this time when public trust has eroded. In two chapters, Patrick O’Leary and Katrice Bridges Copeland address the strategies that the United States government uses to prosecute industry transgressions. Alla Digilova, Barbara Bierer, Mark Barnes, and Rebecca Li discuss trends toward transparency in clinical trial data, which end an industry monopoly on this information. Genevieve Pham-Kanter provides a novel empirical analysis, which shows how industry financial ties are related to the votes of U.S. Food and Drug Administration (FDA) advisory board members.

This document is currently not available here.

Link to Publisher Site Link to Publisher Site (BU Community Subscription)

Share

COinS